Macquarie Group Ltd. Raises Holdings in PerkinElmer, Inc. (PKI)

Macquarie Group Ltd. boosted its position in PerkinElmer, Inc. (NYSE:PKI) by 34.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,700 shares of the medical research company’s stock after buying an additional 14,400 shares during the quarter. Macquarie Group Ltd. owned approximately 0.05% of PerkinElmer worth $3,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Acrospire Investment Management LLC boosted its stake in shares of PerkinElmer by 185.7% during the second quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 1,300 shares during the period. LS Investment Advisors LLC boosted its stake in shares of PerkinElmer by 2.1% during the second quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 60 shares during the period. Carret Asset Management LLC purchased a new stake in shares of PerkinElmer during the second quarter valued at approximately $210,000. Cipher Capital LP purchased a new stake in shares of PerkinElmer during the second quarter valued at approximately $230,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of PerkinElmer by 9.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,870 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 318 shares during the period. 91.66% of the stock is owned by institutional investors and hedge funds.

Shares of PerkinElmer, Inc. (NYSE PKI) traded down $0.56 during trading on Friday, hitting $73.12. The company had a trading volume of 467,175 shares, compared to its average volume of 619,393. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.09 and a current ratio of 2.59. The company has a market capitalization of $8,059.65, a P/E ratio of 26.30, a PEG ratio of 2.19 and a beta of 0.77. PerkinElmer, Inc. has a one year low of $50.51 and a one year high of $74.11.

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 9th. Investors of record on Friday, January 19th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.38%. PerkinElmer’s dividend payout ratio is presently 7.78%.

A number of research firms have recently weighed in on PKI. ValuEngine lowered PerkinElmer from a “buy” rating to a “hold” rating in a research note on Friday. Citigroup reissued a “buy” rating and set a $80.00 price objective (up previously from $74.00) on shares of PerkinElmer in a research note on Tuesday, September 26th. Cowen reissued a “hold” rating and set a $70.00 price objective on shares of PerkinElmer in a research note on Friday, September 1st. Robert W. Baird reissued a “buy” rating and set a $72.00 price objective on shares of PerkinElmer in a research note on Friday, October 20th. Finally, Morgan Stanley reissued an “overweight” rating and set a $77.00 price objective (down previously from $79.00) on shares of PerkinElmer in a research note on Friday, October 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company’s stock. PerkinElmer has a consensus rating of “Hold” and a consensus price target of $68.64.

In related news, Director Alexis P. Michas sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $73.18, for a total transaction of $365,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas A. Lopardo sold 24,050 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $70.72, for a total value of $1,700,816.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,121 shares of company stock valued at $2,569,252. 2.20% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.com-unik.info/2017/12/03/macquarie-group-ltd-raises-holdings-in-perkinelmer-inc-pki.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

What are top analysts saying about PerkinElmer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PerkinElmer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit